

Online Research @ Cardiff

This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository: <https://orca.cardiff.ac.uk/id/eprint/99269/>

This is the author's version of a work that was submitted to / accepted for publication.

Citation for final published version:

El-Hiti, Gamal A., Abdel-Wahab, Bakr F., Hegazy, Amany S. and Kariuki, Benson M. ORCID: <https://orcid.org/0000-0002-8658-3897> 2017. Crystal structure of (E)-2-(5-(4-fluorophenyl)-3-(furan-2-yl)-4,5-dihydro-1H-pyrazol-1-yl)-5-((4-fluorophenyl)diazanyl)-4-methylthiazole, C₂₃H₁₇F₂N₅OS. Zeitschrift für Kristallographie - New Crystal Structures 232 (3) , pp. 413-415. 10.1515/ncrs-2016-0293 file

Publishers page: <http://dx.doi.org/10.1515/ncrs-2016-0293>
<<http://dx.doi.org/10.1515/ncrs-2016-0293>>

Please note:

Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher's version if you wish to cite this paper.

This version is being made available in accordance with publisher policies.


See

<http://orca.cf.ac.uk/policies.html> for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.



Gamal A. El-Hiti*, Bakr F. Abdel-Wahab, Amany S. Hegazy and Benson M. Kariuki

Crystal structure of (*E*)-2-(5-(4-fluorophenyl)-3-(furan-2-yl)-4,5-dihydro-1*H*-pyrazol-1-yl)-5-((4-fluorophenyl)diazenyl)-4-methylthiazole, $C_{23}H_{17}F_2N_5OS$



DOI 10.1515/ncrs-2016-0293

Received October 3, 2016; accepted February 16, 2017; available online March 18, 2017

Abstract

$C_{23}H_{17}F_2N_5OS$, monoclinic, $P2_1/c$ (no. 14), $a = 5.2272(4)$ Å, $b = 26.7398(15)$ Å, $c = 15.2645(10)$ Å, $\beta = 97.726(7)^\circ$, $V = 2114.2(2)$ Å³, $Z = 4$, $R_{gt}(F) = 0.0547$, $wR_{ref}(F^2) = 0.1371$, $T = 296(2)$ K.

CCDC no.: 1533011

***Corresponding author: Gamal A. El-Hiti**, Cornea Research Chair, Department of Optometry, College of Applied Medical Sciences, King Saud University, P.O. Box 10219, Riyadh 11433, Saudi Arabia, e-mail: gelhiti@ksu.edu.sa. <http://orcid.org/0000-0001-6675-3126>
Bakr F. Abdel-Wahab: Department of Chemistry, College of Science and Humanities, Shaqra University, Duwadimi, Saudi Arabia; and Applied Organic Chemistry Department, National Research Centre, Dokki, Giza, Egypt

Amany S. Hegazy and Benson M. Kariuki: School of Chemistry, Cardiff University, Main Building, Park Place, Cardiff CF10 3AT, UK

© 2017 Gamal A. El-Hiti et al., published by De Gruyter.

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Table 1: Data collection and handling.

Crystal:	Orange needle
Size:	$0.82 \times 0.27 \times 0.06$ mm
Wavelength:	Mo $K\alpha$ radiation (0.71073 Å)
μ :	2.0 cm^{-1}
Diffractometer, scan mode:	SuperNova, ω -scans
$2\theta_{\text{max}}$, completeness:	59.4° , $>84\%$ (99% to $50.4^\circ 2\theta$)
$N(hkl)_{\text{measured}}$, $N(hkl)_{\text{unique}}$, R_{int} :	10634, 5088, 0.031
Criterion for I_{obs} , $N(hkl)_{\text{gt}}$:	$I_{\text{obs}} > 2\sigma(I_{\text{obs}})$, 3027
$N(\text{param})_{\text{refined}}$:	290
Programs:	CrysAlis ^{PRO} [14], SHELX [15], PLATON [16]

The asymmetric unit of the title crystal structure is shown in the figure. Tables 1 and 2 contain details on crystal structure and measurement conditions and a list of the atoms including atomic coordinates and displacement parameters.

Source of material

The title compound was synthesized from reaction of a mixture of 1:1 molar ratios of 5-(4-fluorophenyl)-3-(furan-2-yl)-4,5-dihydro-1*H*-pyrazole-1-carbothioamide and *N'*-(4-fluorophenyl)-2-oxopropanehydrazonoyl chloride in ethanol under reflux condition for 2 h. The solid obtained on cooling was recrystallized from dimethylformamide to give the title compound as orange crystals in 64% yield, Mp. 225–226 °C [1].

Experimental details

All hydrogen atoms were placed in calculated positions and refined using a riding model. Methyl, methylene and methine C—H bonds were fixed at 0.96 Å, 0.97 Å and 0.98 Å respectively. Displacement parameters were 1.5 times $U_{eq}(C)$ for methyl groups and 1.2 times $U_{eq}(C)$ for methylene and methine hydrogens. Methyl groups were allowed to spin about the C—C bond. Aromatic C—H distances were set to 0.93 Å and their U_{iso} set to 1.2 times $U_{eq}(C)$.

Table 2: Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å²).

Atom	x	y	z	<i>U</i> _{iso} [*] / <i>U</i> _{eq}
C1	0.6495(5)	0.04738(10)	0.59780(18)	0.0655(7)
H1	0.7744	0.0224	0.6059	0.079*
C2	0.6361(5)	0.08585(10)	0.65183(18)	0.0649(7)
H2	0.7473	0.0926	0.7033	0.078*
C3	0.4207(5)	0.11438(10)	0.61618(17)	0.0615(7)
H3	0.3617	0.1436	0.6396	0.074*
C4	0.3163(5)	0.09110(8)	0.54141(15)	0.0500(6)
C5	0.0979(5)	0.10124(8)	0.47659(15)	0.0484(5)
C6	−0.0673(5)	0.14694(9)	0.47670(16)	0.0561(6)
H6A	0.0359	0.1772	0.4797	0.067*
H6B	−0.1676	0.1465	0.5257	0.067*
C7	−0.2426(5)	0.14272(8)	0.38738(15)	0.0511(6)
H7	−0.4242	0.1455	0.3963	0.061*
C8	−0.1805(4)	0.18103(8)	0.32111(15)	0.0474(5)
C9	−0.3144(5)	0.22552(9)	0.31469(19)	0.0663(7)
H9	−0.4475	0.2306	0.3485	0.080*
C10	−0.2526(8)	0.26247(12)	0.2587(3)	0.0966(13)
H10	−0.3431	0.2925	0.2542	0.116*
C11	−0.0596(9)	0.25460(16)	0.2104(2)	0.1000(14)
C12	0.0778(7)	0.21132(16)	0.21420(19)	0.0889(11)
H12	0.2106	0.2070	0.1800	0.107*
C13	0.0149(5)	0.17366(10)	0.27052(16)	0.0610(7)
H13	0.1049	0.1436	0.2739	0.073*
C14	−0.3075(5)	0.06521(8)	0.29387(15)	0.0510(6)
C15	−0.4537(5)	0.00457(9)	0.18424(16)	0.0521(6)
C16	−0.5903(5)	0.04815(9)	0.17850(16)	0.0534(6)
C17	−0.8163(5)	0.05989(11)	0.11044(18)	0.0706(8)
H17A	−0.9659	0.0658	0.1391	0.106*
H17B	−0.8485	0.0322	0.0705	0.106*
H17C	−0.7791	0.0892	0.0780	0.106*
C18	−0.3962(5)	−0.11526(9)	0.09743(16)	0.0549(6)
C19	−0.6020(6)	−0.12125(11)	0.0320(2)	0.0775(9)
H19	−0.7214	−0.0956	0.0198	0.093*
C20	−0.6318(7)	−0.16490(13)	−0.0153(2)	0.0914(10)
H20	−0.7712	−0.1691	−0.0594	0.110*
C21	−0.4549(6)	−0.20178(11)	0.00311(19)	0.0728(8)
C22	−0.2510(6)	−0.19752(11)	0.0663(2)	0.0793(9)
H22	−0.1328	−0.2235	0.0777	0.095*
C23	−0.2219(6)	−0.15362(11)	0.1137(2)	0.0751(8)
H23	−0.0816	−0.1499	0.1576	0.090*
N1	0.0261(4)	0.07057(7)	0.41315(13)	0.0538(5)
N2	−0.1851(4)	0.09153(7)	0.36206(13)	0.0564(5)
N3	−0.5072(4)	0.08338(7)	0.24102(13)	0.0548(5)
N4	−0.5024(4)	−0.03614(8)	0.13060(13)	0.0567(5)
N5	−0.3458(4)	−0.07204(8)	0.15071(13)	0.0579(5)
O1	0.4563(3)	0.04935(6)	0.52908(11)	0.0641(5)
F1	0.0032(6)	0.29140(10)	0.15608(16)	0.1654(13)
F2	−0.4863(4)	−0.24579(7)	−0.04261(13)	0.1111(7)
S1	−0.20373(13)	0.00572(2)	0.27253(4)	0.0553(2)

Discussion

Many pyrazolylthiazoles have been synthesized using different procedures and showed antinociceptive,

anti-inflammatory and antimicrobial activities [2–10]. The X-ray crystal structures for related compounds have been published recently [11, 12].

The asymmetric unit consists of one molecule. In the molecule, the furan(A)-pyrazole(B)-thiazole(C)-fluorophenyl(D) ring system is almost planar. Thus the largest deviation from the least-squares plane through the four rings is 0.22(1) Å (by O1). The greatest difference between the planes through adjacent rings (A and B) is 7.1(2)°. The second fluorophenyl group (E) is almost perpendicular (85.0(5)°) to the A—B—C—D system. In the crystal, pairs of molecules related by an inversion centre interact through two edge-to-face interactions involving rings D and E with centroid-to-centroid distances of 5.3 Å. A short intermolecular O···O contact (2.84 Å) occurs between furan moieties of pairs of molecules related by inversion symmetry. Such contact is not unique, as shown by a search of the CSD [13] which gave 78 hits for contacts within the sum of van-der-Waals radii for furan oxygens.

Acknowledgements: The project was supported by King Saud University, Deanship of Scientific Research, Research Chair.

References

1. Abdel-Wahab, B. F.; Sediek, A.; Mohamed, H. A.; Awad, G. E. A.: Novel 2-pyrazolin-1-ylthiazoles as potential antimicrobial agents. *Lett. Drug Design Discov.* **10** (2013) 111–118.
2. Prokopp, C. R.; Rubin, M. A.; Sauzem, P. D.; de Souza, A. H.; Berlese, D. B.; Lourega, R. V.; Muniz, M. N.; Bonacorso, H. G.; Zanatta, N.; Martins, M. A.; Mello, C. F.: A pyrazolyl-thiazole derivative causes antinociception in mice. *Braz. J. Med. Biol. Res.* **39** (2006) 795–799.
3. Donohue, B. A.; Michelotti, E. L.; Reader, J. C.; Reader, V.; Stirling, M.; Tice, C. M.: Design, synthesis, and biological evaluation of a library of 1-(2-Thiazolyl)-5-(trifluoromethyl)pyrazole-4-carboxamides. *J. Comb. Chem.* **4** (2002) 23–32.
4. Khloya, P.; Kumar S.; Kaushik, P.; Surain, P.; Kaushik, D.; Sharma, P. K.: Synthesis and biological evaluation of pyrazolylthiazole carboxylic acids as potent anti-inflammatory–antimicrobial agents. *Bioorg. Med. Chem. Lett.* **25** (2015) 1177–1181.
5. Ye, L.; Knapp, J. M.; Sangwung, P.; Fetting, J. C.; Verkman, A. S.; Kurth, M. J.: Pyrazolylthiazole as ΔF508-cystic fibrosis transmembrane conductance regulator correctors with improved hydrophilicity compared to bithiazoles. *J. Med. Chem.* **53** (2010) 3772–3781.
6. Denisova, A. B.; Sosnovskikh, V. Y.; Dehaen, W.; Toppet, S.; Meervelt, L. V.; Bakulev, V. A.: The regioselectivity of the formation of 2-pyrazolylthiazoles and their precursors from the reaction of 2-hydrazinothiazoles with 4,4,4-trifluoro-1-hetaryl-1,3-butanediones. *J. Fluorine Chem.* **115** (2002) 183–192.
7. Abdel-Wahab, B. F.; Mohamed, H. A.; Awad, G. E. A.: Synthesis and antimicrobial activity of some new

- 3-(4-fluorophenyl)benzo[g]indazoles and 1-pyrazolylthiazoles. Eur. Chem. Bull. **3** (2014) 1069–1074.
8. Salem, M. E.; Darweesh, A. F.; Mekky, A. E. M.; Farag, A. M.; Elwahy, A. H. M.: 2-Bromo-1-(1*H*-pyrazol-4-yl)ethanone: versatile precursor for novel mono- and *bis* [pyrazolylthiazoles]. J. Heterocycl. Chem. **54** (2017) 226–234.
 9. Hassan, A. A.; Bebair, T. M.; El-Gamal, M. I.: Synthesis of pyrazolylthiazole and pyrazolyl-1,2,4-triazepine derivatives. J. Chem. Res. **38** (2014) 27–31.
 10. Mohamed, H. A.; Abdel-Latif, E.; Abdel-Wahab, B. F.; Awad, G. E. A.: Novel antimicrobial agents: fluorinated 2-(3-(benzofuran-2-yl) pyrazol-1-yl)thiazoles. Int. J. Med. Chem. **2013** (2013) Article ID 986536. doi: 10.1155/2013/986536.
 11. El-Hiti, G. A.; Abdel-Wahab, B. F.; Baashen, M.; Ghabbour, H. A.: Crystal structure of 2-(3-(benzofuran-2-yl)-5-(4-fluorophenyl)-4,5-dihydro-1*H*-pyrazol-1-yl)-4-(4-chlorophenyl)thiazole, C₂₆H₁₇ClF₂N₅OS. Z. Kristallogr. - NCS **231** (2016) 911–912.
 12. El-Hiti, G. A.; Abdel-Wahab, B. F.; Ajarim, M. D.; Alobaid, A. M.; Ghabbour, H. A.: Crystal structure of 2-(3-(benzofuran-2-yl)-5-phenyl-4,5-dihydro-1*H*-pyrazol-1-yl)-4-phenylthiazole, C₂₆H₁₉N₃OS. Z. Kristallogr. - NCS **231** (2016) 935–936.
 13. Groom, C. R.; Bruno, I. J.; Lightfoot, M. P.; Ward, S. C.: The Cambridge Structural Database. Acta Crystallogr. **B72** (2016) 171–179.
 14. Agilent. CrysAlis^{PRO}. Agilent Technologies, Yarnton, England (2014).
 15. Sheldrick, G. M.: A short history of SHELX. Acta Crystallogr. **A64** (2008). 112–122.
 16. Farrugia, L. J.: WinGX and ORTEP for Windows: an update. J. Appl. Crystallogr. **45** (2012). 849–854.